Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

Summary

A Phase IIIb, Multicenter, Open-Label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 to Power Disc-15 With the I-neb® Adaptive Aerosol Delivery® System (I-neb® AAD®)

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Signed informed consent prior to initiation of any study-mandated procedure.
•Male or female patients aged 18-85 years.
•Patients with symptomatic pulmonary arterial hypertension in New York Heart Association (NYHA) functional class III or IV at the time of initiation of iloprost inhalation (Ventavis®) therapy using the Power Disc-6 (PD-6).
•Patients with the following types of pulmonary arterial hypertension (PAH) belonging to World Health Organization (WHO) Group I:
•* 1.1: Idiopathic (IPAH)
•* 1.2: Familial (FPAH)
•* 1.3: Associated with (APAH)
•* 1.3.1: Collagen vascular disease
•* 1.3.2: Congenital systemic-to-pulmonary shunts at least 2 years post surgical repair
•* 1.3.4: Human immunodeficiency virus (HIV) infection
+51 more criteria

Exclusion Criteria

•PAH belonging to WHO group II-V.

Locations (36)

University of South Alabama Medical

Mobile, Alabama, United States

Arizona Pulmonary Associates, Ltd.

Phoenix, Arizona, United States

Kaiser Foundation Hospital

Los Angeles, California, United States

West Los Angeles VA Healthcare Center

Los Angeles, California, United States

Santa Barbara Cottage Hospital

Santa Barbara, California, United States

University of Florida

Gainesville, Florida, United States

Central Florida Pulmonary Group

Orlando, Florida, United States

Suncoast Lung Research, LLC

Sarasota, Florida, United States

Northwestern University

Chicago, Illinois, United States

Kentuckiana Pulmonary Associates

Louisville, Kentucky, United States

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension

COMPERA / COMPERA-KIDS

The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization